

DAFTAR PUSTAKA

- Abdullah, M. and Gunawan, J. (2012) “Dispepsia,” *CDK-197*, 39(9), pp. 647–651.
- Adachi, T. *et al.* (2017) “Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for *Helicobacter pylori*” *Oncology*, 93(1), pp. 15–19. doi:10.1159/000481224.
- Alba, C., Blanco, A. and Alarcón, T. (2017) “Antibiotic resistance in *Helicobacter pylori*,” *Current Opinion in Infectious Diseases*, 30(5), pp. 489–497. doi:10.1097/QCO.0000000000000396.
- Angelia, J. and Sutanto, H. (2019) “Hubungan Kecemasan Dengan Derajat Keparahan Dispepsia Pada Mahasiswa Fakultas Kedokteran Universitas Tarumanegara Angkatan 2014,” *Tarumanegara Medical Journal*, 2(1), pp. 77–83.
- Banerjee, A. and Chaudhury, S. (2010) “Statistics without tears: Populations and samples,” *Industrial Psychiatry Journal*, 19(1), p. 60.
- Brunton, L., Chabner, B. and Knollmann, B. (2018) *Goodman & Gilman’s The pharmacological basis of therapeutics*. 13th edn. New York: McGraw-Hill Medical.
- Bujanda, L. *et al.* (2021) “Antibiotic Resistance Prevalence and Trends in Patients Infected with *Helicobacter pylori* in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg),” *Antibiotics*, 10(9). doi:10.3390/antibiotics10091058.
- Cammarota, G. *et al.* (1996) “*Helicobacter pylori* eradication using one-week low-dose lansoprazole plus amoxicillin and either clarithromycin or azithromycin,” *Alimentary Pharmacology & Therapeutics*, 10(6), pp. 997–1000. doi:10.1046/j.1365-2036.1996.d01-533.x.
- Carroll, K. *et al.* (2016) *Jawetz, Melnick & Adelberg’s Medical Microbiology*. 27th edn. New York: McGraw-Hill Education.
- Chen, M.-C. *et al.* (2014) “Levofloxacin-Amoxicillin/Clavulanate-Rabeprazole versus a Standard Seven-Day Triple Therapy for Eradication of *Helicobacter pylori* Infection,” *BioMed Research International*, 2014, pp. 1–7. doi:10.1155/2014/158520.
- Choi, H.S. (2012) “Comparison of sequential and 7-, 10-, 14-d triple therapy for *Helicobacter pylori* infection,” *World Journal of Gastroenterology*, 18(19), p. 2377. doi:10.3748/wjg.v18.i19.2377.
- Dewi, A. (2017) *Hubungan Pola Makan Dan Karakteristik Individu Terhadap Sindrom Dispepsia Pada Mahasiswa Angkatan 2015 Dan 2016 Fakultas Kedokteran Univeritas Hasanuddin*.
- Diaconu, S. *et al.* (2017) “*Helicobacter pylori* infection: old and new,” *Journal of medicine and life*, 10(2), pp. 112–117.

- Djojoningrat, D. (2014) “Dispepsia Fungsional,” in Setiati, S. et al. (eds) *Buku Ajar Ilmu Penyakit Dalam Jilid I*. 6th edn. Jakarta: Internal Publishing, pp. 1805–1809.
- Furuta, T. *et al.* (2014) “Effect of dosing schemes of amoxicillin on eradication rates of *Helicobacter pylori* with amoxicillin-based triple therapy,” *The Journal of Clinical Pharmacology*, 54(3), pp. 258–266. doi:10.1002/jcph.195.
- García-Rayado, G., Navarro, M. and Lanás, A. (2018) “NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs,” *Expert Review of Clinical Pharmacology*, 11(10), pp. 1031–1043. doi:10.1080/17512433.2018.1516143.
- Gunawan, S.G. *et al.* (eds) (2016) *Farmakologi Dan Terapi*. 6th edn. Jakarta: Badan Penerbit FKUI.
- Gungor, G. *et al.* (2015) “Current Status of Five Different Regimens for Empiric First-Line *Helicobacter pylori* Eradication in Turkey,” *Digestion*, 92(2), pp. 55–59. doi:10.1159/000434627.
- Hajaghamohammadi, A. *et al.* (2014) “Low Dose Furazolidone for Eradication of H- *pylori* Instead of Clarithromycin: A Clinical Trial,” *Global Journal of Health Science*, 7(1). doi:10.5539/gjhs.v7n1p235.
- Kao, C.Y., Sheu, B.S. and Wu, J.J. (2016) “*Helicobacter pylori* infection: An overview of bacterial virulence factors and pathogenesis,” *Biomedical journal*, 39(1), pp. 14–23.
- Khoshnood, A. *et al.* (2014) “Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of *Helicobacter pylori*: A randomized clinical trial.,” *Journal of medicine and life*, 7(2), pp. 254–9.
- Kim, T.H. *et al.* (2020) “Comparison of 7- and 14-Day Eradication Therapy for *Helicobacter pylori* with First- and Second-Line Regimen: Randomized Clinical Trial,” *Journal of Korean Medical Science*, 35(5). doi:10.3346/jkms.2020.35.e33.
- Koduru, P., Irani, M. and Quigley, E.M.M. (2018) “Definition, Pathogenesis, and Management of That Cursed Dyspepsia,” *Clinical Gastroenterology and Hepatology* [Preprint]. doi:10.1016/j.cgh.2017.09.002.
- Leow, A.H. -R. *et al.* (2018) “Optimizing first line 7-day standard triple therapy for *Helicobacter pylori* eradication: Prolonging treatment or adding bismuth: which is better?,” *Journal of Digestive Diseases*, 19(11), pp. 674–677. doi:10.1111/1751-2980.12679.
- Li, B. *et al.* (2020a) “Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for *Helicobacter pylori*: A meta-analysis,” *Microbial Pathogenesis*, 142, p. 104075. doi:10.1016/j.micpath.2020.104075.
- Li, B. *et al.* (2020b) “Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for *Helicobacter pylori*: A

meta-analysis,” *Microbial Pathogenesis*, 142.
doi:10.1016/j.micpath.2020.104075.

- Loghmani, H. *et al.* (2012a) “Clarithromycin versus metronidazole in first-line *Helicobacter pylori* eradication. Prospective randomized study of 85 Tunisian adults,” *La Tunisie medicale*, 90(1), pp. 31–5.
- Loghmani, H. *et al.* (2012b) “Clarithromycin versus metronidazole in first-line *Helicobacter pylori* eradication. Prospective randomized study of 85 Tunisian adults,” *La Tunisie medicale*, 90(1), pp. 31–5.
- Madisch, A. *et al.* (2018) “The Diagnosis and Treatment of Functional Dyspepsia,” *Deutsches Ärzteblatt international* [Preprint].
doi:10.3238/arztebl.2018.0222.
- Marques, A.T. *et al.* (2020) “Trends in *Helicobacter pylori* resistance to clarithromycin: from phenotypic to genomic approaches,” *Microbial Genomics*, 6(3). doi:10.1099/mgen.0.000344.
- Miller, M., Barrett, S. and Henderson, D. (2006) “Control and Eradication,” in Jamison, D., Breman, J., and Measham, A. (eds) *Disease Control Priorities in Developing Countries*. 2nd edn. Washington (DC): The International Bank for Reconstruction and Development / The World Bank.
- Mohammadi, M. *et al.* (2017) “Furazolidone, an Underutilized Drug for *H. pylori* Eradication: Lessons from Iran,” *Digestive diseases and sciences*, 62(8), pp. 1890–1896.
- Murata, M. *et al.* (2020) “Clarithromycin Versus Metronidazole in First-Line *Helicobacter Pylori* Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis,” *Journal of Clinical Medicine*, 9(2), p. 543. doi:10.3390/jcm9020543.
- Nayar, D. (2018) “Current eradication rate of *Helicobacter pylori* with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area,” *Infect Drug Resist*, 11, pp. 205–211.
- Nishizawa, T. *et al.* (2015) “Clarithromycin Versus Metronidazole as First-line *Helicobacter pylori* Eradication,” *Journal of Clinical Gastroenterology*, 49(6), pp. 468–471. doi:10.1097/MCG.000000000000165.
- Notoatmodjo, S. (2018) *Metodologi Penelitian Kesehatan*. Jakarta: PT Rineka Cipta.
- Onyekwere, C.A. (2014) “Rabeprazole, clarithromycin, and amoxicillin *Helicobacter pylori* eradication therapy: Report of an efficacy study,” *World Journal of Gastroenterology*, 20(13), p. 3615. doi:10.3748/wjg.v20.i13.3615.
- Page, M. *et al.* (2021) “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” *BMJ*, p. 71.
- Pramono, L. and Syam, A. (2014) “Recent Updates of *Helicobacter pylori* Infection: from Epidemiology Study to Guideline Issues,” *The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy*, 15(1).

- Prasertpetmanee, S., Mahachai, V. and Vilaichone, R. (2013) “Improved Efficacy of Proton Pump Inhibitor - Amoxicillin - Clarithromycin Triple Therapy for *Helicobacter pylori* Eradication in Low Clarithromycin Resistance Areas or for Tailored Therapy,” *Helicobacter*, 18(4), pp. 270–273. doi:10.1111/hel.12041.
- Rakici, H. *et al.* (2014) “Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for *Helicobacter pylori* infection: Patients’ compliance and bacterial eradication rates,” *Journal of Digestive Diseases*, 15(9), pp. 508–513. doi:10.1111/1751-2980.12171.
- Sarkeshikian, S.S., Iranikhah, A. and Ghadir, M.R. (2013) “Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of *Helicobacter pylori* infection in Iran: a randomized controlled clinical trial,” *The Turkish Journal of Gastroenterology*, 24(1), pp. 10–14. doi:10.4318/tjg.2013.0540.
- Savoldi, A. *et al.* (2018) “Prevalence of Antibiotic Resistance in *Helicobacter pylori*: A Systematic Review and Meta-analysis in World Health Organization Regions,” *Gastroenterology*, 155(5), pp. 1372-1382.e17. doi:10.1053/j.gastro.2018.07.007.
- Shahbazi, S. and Vahdat Shariatpanahi, Z. (2018) “Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and *Helicobacter pylori* eradication: A randomized controlled trial,” *Indian Journal of Gastroenterology*, 37(6), pp. 550–554. doi:10.1007/s12664-018-0916-z.
- Silbernagl, S. and Lang, F. (2016) *Color Atlas of Pathophysiology*. 3rd edn. New York: Thieme.
- Silva, F.M. *et al.* (2008) “Short-term triple therapy with azithromycin for *Helicobacter pylori* eradication: Low cost, high compliance, but low efficacy,” *BMC Gastroenterology*, 8(1), p. 20. doi:10.1186/1471-230X-8-20.
- Simadibrata, M. *et al.* (2014) *Penatalaksanaan Dispepsia dan Infeksi Helicobacter pylori KONSENSUS NASIONAL Editor*. Jakarta.
- Simadibrata, M. (2018) “Role of *Helicobacter pylori* in Damaging the Gastroduodenal Mucosa,” *The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy*, 19(1).
- Sleisenger, M. *et al.* (2016) *Sleisenger & Fordtran’s Gastrointestinal and liver disease*. 10th edn. Philadelphia, PA: Saunders-Elsevier.
- Stanghellini, V. (2017) “Functional Dyspepsia dan Irritable Bowel Syndrome: Beyond Rome IV,” *Digestive Diseases*, 35(1).
- Syam, A. (2013) “Dyspepsia dan *Helicobacter pylori* Infection,” *The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy*, 14(1), p. 1.
- Talley, N.J. (2017) “Functional Dyspepsia: Advances in Diagnosis and Therapy,” *Gut and Liver*, 11(3), pp. 349–357. doi:10.5009/gnl16055.

- Talley, N.J. and Cook, D.R. (2019) “Functional Dyspepsia,” in *Essential Medical Disorders of the Stomach and Small Intestine*. Cham: Springer International Publishing, pp. 155–172. doi:10.1007/978-3-030-01117-8_8.
- Uman, L.S. (2011) “Systematic reviews and meta-analyses.,” *Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l’Academie canadienne de psychiatrie de l’enfant et de l’adolescent*, 20(1), pp. 57–9.
- Wang, J. *et al.* (2015) “Two-week triple therapy has a higher Helicobacter pylori eradication rate than 1-week therapy: A single-center randomized study,” *Saudi Journal of Gastroenterology*, 21(6), p. 355. doi:10.4103/1319-3767.170951.
- Wenzhen, Y. *et al.* (2009) “Moxifloxacin-Based Triple Therapy Versus Clarithromycin-Based Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials,” *Internal Medicine*, 48(24), pp. 2069–2076. doi:10.2169/internalmedicine.48.2344.